Metrics raised 1
- Annual DMF filing target increased to 6-7 per year (from 2-3 previously)
Event Participants
Executives
5 Anish Swadi, Kuldeep Jain, Manoj Mehrotra, Ravi Kapoor, Sameer Hiremath
Analysts
3 Aman Gora, Raghuram Kuchi, Rohit Sinha
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹403 crore | Q1 FY27 reported revenue, showing recovery from regulatory-led disruption in previous year |
| EBITDA | ₹37 crore | EBITDA margin at 9.2%, supported by improving customer ordering patterns and product mix |
| PAT | ₹-7 crore | Net loss of ₹7 crore, impacted by remediation costs and crop division losses |
| EBITDA Margin | 9.2% | Improving sequentially with better product mix across regulated markets and increasing CDMO partnerships |
| Pharma Revenue | ₹233 crore | Year-on-year growth despite planned plant shutdown for US FDA remediation; margins improved in division |
| Pharma EBITDA | ₹8 crore | Margin of 3.2%; capacity utilization at 55-60% due to shutdowns |
| Crop Protection Revenue | ₹170 crore | Mixed quarter with sequential growth in own products, but export demand subdued |
| Crop Protection EBITDA | ₹-6 crore | Margins under pressure from elevated raw material costs and Chinese competition |
| Net Debt | ₹685 crore | Reduced from ₹815 crore in FY24 despite ₹900 crore capex over 4 years |
| Debt-to-Equity | 0.53 | Improved sequentially from 0.56 in March quarter |
| Capital Expenditure | ₹45 crore | Q1 capex focused on de-bottlenecking, regulatory upgrades, and new capacities |
Geographic & Segment Commentary
Pharmaceuticals: Revenue of ₹233 crore with EBITDA margin of 3.2%, supported by improving demand across API and CDMO businesses. Customer ordering patterns are normalizing with facilities at Panoli and Bangalore operating at 55-60% capacity utilization. Focus remains on high-growth therapeutic segments including CNS, anti-diabetics, gastroenterology, oncology, urology, and anti-migraine, with expansion into Latin America, Japan, and Korea.
Crop Protection: Revenue of ₹170 crore with negative EBITDA of ₹6 crore. Own product segment delivered sequential growth supported by improving domestic demand, but CDMO export demand remained subdued with customer orders deferred. Global channel inventories have largely normalized after two years of de-stocking, though ordering remains need-based with pricing pressure from China.
Animal Health: Delivered another strong quarter with healthy volume growth across API and intermediate segments, supported by repeat NCE campaign supplies for leading innovators. Completed US EPA and Canada PMRA regulatory filings for a particular molecule, with long-term contracts in place with global innovators. Business scaled to ₹100 crore+ annual turnover last year with target of ₹400 crore-plus by FY30.
Personal Care: Newly commissioned dedicated multipurpose manufacturing line at Panoli with commercial production commenced; revenues expected by end of FY27. Part of strategy to diversify into adjacent higher-growth segments while leveraging existing manufacturing capabilities.
Company-Specific & Strategic Commentary
US FDA Remediation: Warning letter received in August 2025; remediation program on track with re-inspection expected towards end of FY27. No customer contracts lost—86 customer audits completed in last year with all facilities re-approved. Three global regulatory authorities cleared facilities post-FDA inspection.
DMF Filing Expansion: Newly commissioned pilot plant at Panoli enables increase in DMF filings from 2-3 annually to 6-7 filings per year, significantly strengthening future pipeline.
Capital Allocation: Over last 4 years, invested ₹900 crore in capex—₹300 crore maintenance and ₹600 crore growth. Repurposed part-impaired agrochemical plant for pharma and animal health CDMO portfolio, which reduces execution timelines by nearly 12 months.
Four-Division Strategy: Transitioning from two-division chemical/agrochemical company to four-division approach with pharma and allied businesses (human pharma, animal health, personal care) expected to represent 70-80% of total business within 2-3 years.
Business Development Expansion: Added four dedicated business development professionals across Japan, North America, and Europe to expand CDMO opportunity pipeline.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | 14% to 16% for FY27 | Strong growth in pharma, marginal growth in crop; momentum accelerates in H2 FY27 |
| EBITDA Growth | 25% to 30% for FY27 | Benefits from improving product mix, recovery in regulated markets, increasing CDMO contribution |
| Q2 FY27 | Substantial YoY growth in revenue and EBITDA | Improving customer ordering patterns and seasonal demand |
| Long-term Revenue CAGR | 15% to 16% annually | Operating leverage improves as fixed costs already invested; pharma expected at 18-19% CAGR |
| Animal Health Revenue | ₹400 crore-plus by FY30 | Based on validated molecules, long-term contracts with innovators, multiple products in pipeline |
| Personal Care Revenue | ₹200 crore-plus within next 3 years | Post-launch year; EBITDA margins expected over 20% |
| Animal Health EBITDA Margins | 20%-plus | Once operational leverage is reached |
| FY28 EBITDA | "Substantially better year" | FDA remediation costs roll off; pending approvals ramp up |
Risks & Constraints
| Risk | Context |
|---|---|
| US FDA Re-inspection | Re-inspection expected end of FY27 but could be delayed by a few months. While no customers lost and 86 audits passed, successful clearance is critical for pending DMF approvals and revenue ramp-up in FY28. |
| Crop Protection Pricing Pressure | Surplus Chinese supply continues to pressure pricing despite improving volumes. Q1 was impacted by ₹7-8 crore of raw material cost increase due to geopolitical tensions in Middle East. |
| Geopolitical Volatility | Raw material and energy costs impacted by Middle East tensions; management noted if war escalates, prices could rise again. Oil price drops expected to normalize pricing by end of Q2. |
| CDMO Order Visibility in Crop | Certain customer orders shifted from H1 to H2 FY27 due to inventory build-up at customer end; recovery in ordering remains steady but cautious. |
| Margin Dilution from FDA Costs | Remediation costs hitting fixed cost numbers and depressing EBITDA margins during FY27; meaningful margin improvement deferred to FY28. |
Q&A Highlights
Animal Health Margins
- Question: What kind of margins should we expect from the animal health business targeting ₹400 crore by FY30? (Aman Gora)
- Answer: Expected EBITDA margins of 20%-plus once operational leverage is reached. (Anish Swadi)
Crop Protection Long-term Outlook
- Question: How should we view the crop protection business over a three-year basis given the challenges? (Aman Gora)
- Answer: Expecting marginal single-digit to high single-digit growth. End customers (5-6 big players) contribute almost 80% of global market value by value and are under pressure. Not investing significantly in crop business; focusing on allied businesses with strict capital allocation. New CDMO contract margins lower than 3-4 years ago due to competitive environment. (Sameer Hiremath)
Company Evolution to Pharma
- Question: Is Hikal positioning itself more as a pharma company going forward? (Aman Gora)
- Answer: Moving to a four-division approach where pharma and allied businesses (human pharma, animal health, personal care) will be 70-80% of total business, with crop at about 30%. Personal care expected to cross ₹200 crore in revenue within next 3 years with over 20% EBITDA margins. (Sameer Hiremath)
FY27 Guidance and Margins
- Question: Given pharma growing faster than crop, shouldn't margins be better than 14-15%? (Aman Gora)
- Answer: FDA remediation costs are hitting fixed costs and depressing EBITDA. Once remediation goes away by end of FY27, meaningful margin improvement will be visible in FY28 and beyond. (Sameer Hiremath)
FDA Clearance Impact on FY28
- Question: How will incremental revenue look in FY28 post US FDA clearance? (Rohit Sinha)
- Answer: Growth will accelerate in FY28 with pending DMF filings receiving approval post-clearance, leading to revenue ramp-up at better margins. (Sameer Hiremath)
Crop Protection Pricing Contracts
- Question: Are contracts being revised given pricing pressure? (Raghuram Kuchi)
- Answer: Some contracts have pass-through provisions, but where competing with China, customers are only partially compensating. Q1 impacted by ₹7-8 crore raw material cost increase from geopolitical tensions. Expect pricing normalization as oil prices drop, but volatility remains. (Sameer Hiremath)
FDA Re-inspection Confidence
- Question: How confident are you of clearing the FDA re-inspection? (Raghuram Kuchi)
- Answer: Working with stage-gate approach with continuous updates to FDA who confirmed company is moving in right direction. Three global regulatory authorities cleared facilities, 86 customer audits passed, zero contracts lost. Innovator pharma customers are hand-holding on documentation. Expect re-inspection by end of FY27, targeting 18-19% pharma CAGR going forward. (Sameer Hiremath)
Animal Health Revenue Target
- Question: Is the ₹400 crore by FY30 confirmed and which markets? (Raghuram Kuchi)
- Answer: Confirmed target based on strategic plan; selling to all markets where innovator customers operate—Europe, US, Japan, Latin America, and ROW. (Anish Swadi)
Key Takeaway
Hikal reported Q1 FY27 revenue of ₹403 crore with EBITDA margin of 9.2% and net loss of ₹7 crore, reflecting continued transition from regulatory-led disruption to execution-led growth. The pharma division delivered revenue of ₹233 crore despite planned US FDA remediation shutdown, while crop protection posted ₹170 crore revenue with ₹6 crore EBITDA loss due to raw material cost inflation and Chinese pricing pressure. Management guided FY27 revenue growth of 14-16% and EBITDA growth of 25-30%, with Q2 expected to show substantial YoY improvement and H2 accelerating further. Strategic transformation continues with DMF filing capability expanded from 2-3 to 6-7 filings annually, four-division portfolio evolution, and animal health targeting ₹400 crore-plus by FY30 at 20%-plus EBITDA margins. Company reduced net debt to ₹685 crore with debt-to-equity at 0.53 while investing ₹900 crore in growth capex. Key watch points remain FDA re-inspection by end of FY27, which is critical for unlocking pending approvals and driving FY28 acceleration, and crop protection pricing recovery dependent on geopolitical stability.